Dominik Schmiedel
Overview
Explore the profile of Dominik Schmiedel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M, et al.
Transfus Med Hemother
. 2025 Feb;
52(1):42-60.
PMID: 39944413
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve...
2.
Stoler-Barak L, Schmiedel D, Sarusi-Portuguez A, Rogel A, Blecher-Gonen R, Haimon Z, et al.
J Exp Med
. 2024 Sep;
221(11).
PMID: 39297882
The establishment of long-lasting immunity against pathogens is facilitated by the germinal center (GC) reaction, during which B cells increase their antibody affinity and differentiate into antibody-secreting cells (ASC) and...
3.
Schindler K, Ruppel K, Muller C, Koehl U, Fricke S, Schmiedel D
Mol Ther Methods Clin Dev
. 2024 Sep;
32(3):101328.
PMID: 39286335
Chimeric antigen receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer. Currently, there are six approved CAR T cell products available on the market that target different...
4.
Grahnert A, Seiffert S, Wenk K, Schmiedel D, Boldt A, Vucinic V, et al.
Biomedicines
. 2024 Aug;
12(8).
PMID: 39200107
For the monitoring of chimeric antigen receptor (CAR) T-cell therapies, antigen-based CAR detection methods are usually applied. However, for each target-antigen, a separate detection system is required. Furthermore, when monitored...
5.
Renner A, Stahringer A, Ruppel K, Fricke S, Koehl U, Schmiedel D
Gene Ther
. 2024 Apr;
31(7-8):378-390.
PMID: 38684788
Allogeneic cell therapies, such as those involving macrophages or Natural Killer (NK) cells, are of increasing interest for cancer immunotherapy. However, the current techniques for genetically modifying these cell types...
6.
Rauch-Wirth L, Renner A, Kaygisiz K, Weil T, Zimmermann L, Rodriguez-Alfonso A, et al.
Front Immunol
. 2023 Nov;
14:1270243.
PMID: 38022685
Chimeric antigen receptor (CAR)-T cell therapy is a groundbreaking immunotherapy for cancer. However, the intricate and costly manufacturing process remains a hurdle. Improving the transduction rate is a potential avenue...
7.
Ciulean I, Fischer J, Quaiser A, Bach C, Abken H, Tretbar U, et al.
Front Immunol
. 2023 Nov;
14:1290488.
PMID: 38022580
Head and neck squamous cell carcinoma (HNSCC) is a major challenge for current therapies. CAR-T cells have shown promising results in blood cancers, however, their effectiveness against solid tumors remains...
8.
Messer E, Meyer A, Klaeske K, Sieg F, Eifert S, Schmiedel D, et al.
Obes Facts
. 2023 May;
16(4):364-373.
PMID: 37232004
Introduction: Infections are a major problem after left ventricular assist device (LVAD) implantation that affects morbidity, mortality, and the quality of life. Obesity often increases the risk for infection. In...
9.
Feigl F, Stahringer A, Peindl M, Dandekar G, Koehl U, Fricke S, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834542
Natural killer (NK) cells are a subset of lymphocytes that offer great potential for cancer immunotherapy due to their natural anti-tumor activity and the possibility to safely transplant cells from...
10.
Strobelt R, Adler J, Paran N, Yahalom-Ronen Y, Melamed S, Politi B, et al.
Sci Rep
. 2022 Apr;
12(1):5758.
PMID: 35388061
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of the COVID-19 pandemic. More than 274 million individuals have suffered from COVID-19 and over five million people...